The MPP invites Expression of Interest from potential sublicensees for licences to manufacture and sell bictegravir, tenovofir alafenamide, tenofovir disoproxil fumarate, dolutegravir, lopinavir, ritonavir and daclatasvir.
EXPANSION OF THE PATENT AND LICENSING DATABASE, MEDSPAL, TO INCLUDE ESSENTIAL MEDICINES FOR CANCER
MedsPaL, a comprehensive resource for information on the intellectual property status of priority medicines in developing countries, has been expanded to patented treatments on the World Health Organization’s Model List of Essential Medicines.
The MPP’s patents and licences database, MedsPaL is an information resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
Geneva, 15 February 2017 - The Medicines Patent Pool (MPP) signed a collaborative agreement with the African Regional Intellectual Property Organization (ARIPO), an intergovernmental organisation that facilitates cooperation among 19 African states in patent and intellectual property issues. ARIPO will support the continued improvement of, and data collection for, MedsPaL, the MPP’s signature resource for patent and licensing information in low- and middle-income countries.
The MPP launched MedsPaL in 2016 to provide information on the patent and licensing status of HIV, hepatitis C and tuberculosis medicines. It expanded the database in late 2017 to include other patented medicines on the World Health Organization’s Essential Medicines List. Today, MedsPaL covers 6,800 national patent applications in more than 110 countries for more than 70 priority treatments.
ARIPO is the second regional patent organisation to sign a collaborative agreement with the MPP. The foundation also has a memorandum of unde...
The Medicines Patent Pool (MPP) is currently inviting interested product developers to indicate an interest in a sublicence for investigational hepatitis C (HCV) treatment ravidasvir. Pharco Pharmaceuticals granted the MPP a non-exclusive, royalty-bearing licence which allows sublicensees to develop, make, have made, use, file for regulatory approval, sell, import and export ravidasvir. The full text of the agreement can be found here.
Per the licence’s terms and conditions, the MPP seeks to grant sublicences to any entity that can demonstrate a willingness and capacity to further develop and commercialise the product and make the product widely available in the Territory. The MPP will also require any sublicensee to agree upon reasonable diligence requirements and development milestones.
Interested parties should also submit as much detail as possible to help MPP understand whether, and to what extent, a granted sublicence will help improve sustainable access to improved regimens to treat HCV. Applicat...
Geneva, 14 December 2017 — The Medicines Patent Pool (MPP) Governance Board announced today that Greg Perry, Executive Director of the foundation since January 2013, has resigned from his post to pursue new opportunities.
In nearly five years with the MPP, Perry has succeeded in establishing the MPP as the leading patent pooling and voluntary licensing mechanism dedicated to ensuring affordable access to medicines for people living in low- and middle-income countries.
“Greg leaves the MPP in a very strong position for its future work in improving treatment options in developing countries. The Board would like to thank him for his invaluable contribution and leadership during his time as Executive Director,” said Marie-Paule Kieny, Chair of the foundation’s Governance Board. “We wish him every success in his next projects.”
During Greg Perry’s tenure, the MPP has gained the confidence of originator and generic pharmaceutical companies, civil society groups, governments and international organisations....
“Successful cooperation of the Ministry of Health of Belarus with the Medicines Patent Pool is crucial in light of our current work to achieve the “90-90-90” goals and put an end to the epidemic in the country which is only possible when access to affordabl...”